Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Omicron
SARS-CoV-2
immunocompromised
resistance
sotrovimab
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 02 2023
08 02 2023
Historique:
received:
23
05
2022
pubmed:
23
7
2022
medline:
11
2
2023
entrez:
22
7
2022
Statut:
ppublish
Résumé
Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.
Identifiants
pubmed: 35867699
pii: 6648554
doi: 10.1093/cid/ciac601
pmc: PMC9384506
doi:
Substances chimiques
sotrovimab
1MTK0BPN8V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e507-e509Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. B. R. received travel support from Pfizer and participated on data and safety monitoring boards or advisory boards for Exevir, AstraZeneca, and Roche. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Lancet Infect Dis. 2022 Jul;22(7):942-943
pubmed: 35690075
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
Nat Med. 2022 Jul;28(7):1501-1508
pubmed: 35725921
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Blood Adv. 2022 Mar 8;6(5):1537-1546
pubmed: 35114690
J Infect Dis. 2023 Jan 11;227(2):206-210
pubmed: 35921542